LIFE Ethos Technologies Inc.

BUSINESS SUMMARY

Ethos Technologies sells term life insurance online. Applicants answer a short questionnaire, the platform runs AI-driven underwriting against partner-carrier rules, and most policies issue in minutes without a medical exam.

Ethos does not carry the insurance risk itself — policies are underwritten by partner carriers, primarily:

• Legal & General America (majority of volume)
• Ameritas

Ethos collects distribution commissions and ongoing fees. Think of it as an insurance-tech distributor with a proprietary underwriting engine, not an insurer.

MARKET OPPORTUNITY

The US term life market is large, mature, and notoriously poorly-served online — most policies are still sold face-to-face by agents. Pandemic-era interest pulled roughly 30% of term life sales into digital channels; the question is whether that share keeps growing or plateaus.

Ethos's sweet spot is shoppers who want:

• Quick, no-exam coverage
• Face value under ~$2M
• A segment traditional carriers handle awkwardly

International expansion is not currently material.

REVENUE QUALITY

Revenue is commission-driven, recognized largely at policy issuance with some trailing fees. That produces the headline 97% gross margin — accurate for a distribution business, but not directly comparable to a traditional insurer's combined ratio.

Quality depends on two things investors don't have full visibility into:

• Persistency — how long policies stay in force after issuance
• Ethos's share of the commission stack — neither is disclosed at the level of detail incumbents like SelectQuote (SLQT) provide

The 60% revenue growth is impressive but should be contextualised against SLQT's historical swings from +60% to −40% year-over-year when rate cycles turn.

COMPETITIVE ADVANTAGE

The AI underwriting engine and the multi-carrier partner network are the claimed moat. Both are credible but imitable — Lemonade (LMND), Root (ROOT), and Policygenius have comparable tech, and incumbent carriers have begun offering their own no-exam instant-issue products directly.

The strongest defensible asset is the 8-year consumer brand and the accumulated claims/underwriting data Ethos feeds back into its models.

Notably, the company operates with negative stockholders' equity (~−$107M book), reflecting cumulative losses and aggressive stock-based compensation. It is a signal of past losses, not current strength.

GROWTH THESIS

The bull case is straightforward: digital term life share keeps expanding, Ethos's unit economics have flipped positive (operating margin 19% on the latest data), and the 2.0× P/S multiple is cheap for a 60%-growth, 97%-gross-margin business if those numbers are sustainable.

The −51% 12-month share-count change is the other half of the thesis — management has been shrinking the float through buybacks and likely a post-SPAC share consolidation, concentrating value per remaining share.

What has to go right:

1. Persistency holds — lapsed policies kill the commission tail
2. CAC stays disciplined — paid-acquisition spend doesn't outrun lifetime value
3. Partner-carrier relationships don't renegotiate commissions downward

KEY RISKS

Three specific risks worth naming:

1. Partner-carrier concentration. Legal & General America reportedly underwrites a majority of Ethos's volume. A commission renegotiation or partnership exit would directly hit revenue.

2. Customer acquisition cost. Digital insurance companies have historically burned cash on paid acquisition. Ethos has improved here, but the path to profit depends on CAC staying below lifetime commission — watch quarterly CAC disclosures closely.

3. Balance-sheet fragility. Negative book equity (~−$107M) and the post-SPAC share-count history mean this is not a clean balance sheet. A recession-driven downturn in applications would quickly expose it.

VERDICT

The 93/100 composite score captures the growth, margins, and shrinking share count well — but misses the structural fragility of the balance sheet and the partner-dependency.

For investors who want exposure to insurance-tech at a relatively modest multiple, LIFE is a legitimate name to research, especially relative to more hyped peers. For conservative investors, the negative equity and CAC sensitivity are disqualifying.

The single metric to watch next is persistency. If Ethos discloses lapse rates, or if the next 10-Q shows commission revenue decelerating faster than new policies, the thesis weakens quickly.